Zafirlukast side‑effect – Churg‑Strauss syndrome - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zafirlukast Side‑Effect – Churg‑Strauss Syndrome: A Complete Medical Guide

Zafirlukast Side‑Effect – Churg‑Strauss Syndrome: A Complete Medical Guide

Overview

Churg‑Strauss syndrome (CSS), also called eosinophilic granulomatosis with polyangiitis (EGPA), is a rare, systemic vasculitis that primarily affects small‑to‑medium‑sized blood vessels. It is characterized by asthma, high levels of eosinophils (a type of white blood cell), and inflammation of various organs, especially the lungs, skin, heart, and nerves.

Who it affects

  • Adults aged 30‑60 years are most commonly diagnosed.
  • Women are slightly more affected than men (approximately 55 % vs. 45 %).
  • Most patients have a long‑standing history of asthma or allergic rhinitis before vasculitic symptoms appear.

Prevalence

  • Incidence in the United States: 1–3 cases per million persons per year.[1] Mayo Clinic
  • Worldwide prevalence is estimated at 10–14 per million.[2] WHO

While zafirlukast is an effective leukotriene receptor antagonist for asthma, rare cases of CSS have been reported after its initiation or dose escalation. The association is thought to be related to the unmasking of underlying eosinophilic disease when corticosteroids are tapered, rather than a direct toxic effect of the drug.[3] NEJM 2020

Symptoms

CSS develops in three overlapping phases—prodromal (allergic), eosinophilic, and vasculitic. Because the disease can affect virtually any organ, symptoms are diverse. Below is a comprehensive list:

Prodromal (Allergic) Phase

  • Asthma: worsening wheeze, dyspnea, or increased need for rescue inhalers.
  • Allergic rhinitis/sinusitis: nasal congestion, sneezing, loss of smell.
  • Upper‑airway polyps: nasal polyps causing obstruction.

Eosinophilic Phase

  • Peripheral eosinophilia: blood eosinophil count >1,500 cells/µL.
  • Lung infiltrates: cough, fleeting pulmonary opacities on X‑ray.
  • Gastrointestinal involvement: abdominal pain, diarrhea, eosinophilic gastroenteritis.
  • Cardiac eosinophilia: myocarditis presenting as chest pain or palpitations.

Vasculitic Phase (Systemic)

  • Skin: palpable purpura, livedo reticularis, nodules, or necrotic ulcers.
  • Peripheral nerves: mononeuritis multiplex—sudden, asymmetric weakness or numbness, often in the feet or hands.
  • Kidneys: hematuria, proteinuria, rapidly progressive glomerulonephritis.
  • Heart: pericarditis, heart failure, coronary vasculitis.
  • Sinus & ear: chronic sinusitis, otitis media, hearing loss.
  • General: fever, weight loss, fatigue, night sweats.

In patients taking zafirlukast, the appearance of new or worsening systemic symptoms—especially neuropathy, skin lesions, or cardiac complaints—should raise suspicion for CSS.[4] Cleveland Clinic

Causes and Risk Factors

Exact cause is unknown, but several mechanisms have been proposed.

Immunologic Factors

  • Autoimmune response leading to antineutrophil cytoplasmic antibodies (ANCA), especially p‑ANCA (MPO‑ANCA) in ~40 % of patients.
  • Th2‑dominant immune profile (high IL‑5, IL‑13) promotes eosinophil proliferation.

Drug‑Related Triggers

  • Zafirlukast: The drug itself rarely causes vasculitis; however, reduction of oral corticosteroids after starting zafirlukast may reveal occult EGPA.[5] JACI 2019
  • Other leukotriene antagonists (e.g., montelukast) have similar reports.

Risk Factors Specific to Zafirlukast Users

  • Long‑standing asthma requiring high‑dose inhaled steroids.
  • Recent tapering of systemic steroids within 3–6 months of starting zafirlukast.
  • Elevated baseline eosinophil count (>1,000 cells/µL) before drug initiation.
  • History of allergic rhinitis or sinus polyps.

Genetic & Environmental Factors

  • HLA‑DRB4 and HLA‑DQ alleles have been linked to higher susceptibility.
  • Exposure to silica dust or certain infections may act as co‑triggers.

Diagnosis

Diagnosing CSS requires a combination of clinical judgment, laboratory data, imaging, and sometimes tissue biopsy. The 1990 American College of Rheumatology (ACR) criteria remain widely used; meeting ≥4 of 6 criteria yields a sensitivity of 85 % and specificity of 99 %.

ACR Classification Criteria

  1. Asthma (mandatory).
  2. Eosinophilia >10 % of total leukocytes or >1,500 cells/µL.
  3. Mononeuritis multiplex or peripheral neuropathy.
  4. Paranasal sinus abnormality.
  5. Pulmonary infiltrates (non‑fixed).
  6. Biopsy showing extravascular eosinophils.

Key Diagnostic Tests

  • Complete blood count (CBC) with differential: Elevated eosinophils.
  • ANCA serology: p‑ANCA (MPO) positive in ~40 % of cases; helps differentiate from other vasculitides.
  • Chest imaging: High‑resolution CT often shows fleeting infiltrates or ground‑glass opacities.
  • Sinus CT: Mucosal thickening, polyps, or bony remodeling.
  • Nerve conduction studies: Document mononeuritis multiplex.
  • Urinalysis & renal function: Detect hematuria, proteinuria.
  • Biopsy (skin, nerve, lung, or muscle): Gold standard to confirm eosinophil‑rich necrotizing vasculitis.

When CSS is suspected in a patient receiving zafirlukast, the clinician should also review medication history, steroid tapering schedules, and baseline eosinophil trends.

Treatment Options

Therapy aims to suppress the abnormal immune response, protect organ function, and prevent relapses. Treatment is stratified by disease severity (organ‑ or life‑threatening involvement vs. limited disease).

Induction Therapy (Control Active Disease)

  • Systemic glucocorticoids: Prednisone 1 mg/kg/day (max 60 mg) for 4‑6 weeks, then gradual taper over 6–12 months. High‑dose steroids are the cornerstone.
  • Immunosuppressive agents (for severe or refractory disease):
    • Cyclophosphamide 2 mg/kg/day PO or IV (15 mg/kg) every 2–3 weeks for 3–6 months.
    • Azathioprine 2 mg/kg/day or Mycophenolate mofetil 2 g/day as steroid‑sparing agents.
  • Biologic therapy: Mepolizumab (anti‑IL‑5) 300 mg SC every 4 weeks is FDA‑approved for EGPA and reduces relapses, especially in patients with asthma‑dominant disease.[6] FDA Label

Maintenance Therapy (Prevent Relapse)

  • Low‑dose prednisone (5‑10 mg/day) combined with azathioprine or methotrexate for 12‑24 months.
  • Continuation of mepolizumab can be considered indefinitely if disease is well‑controlled.

Adjunctive Measures

  • Asthma management: Continue inhaled corticosteroids (ICS) and long‑acting β₂‑agonists; avoid abrupt steroid withdrawal.
  • Anticoagulation: When cardiac involvement includes thrombosis.
  • Physical therapy: For peripheral neuropathy and muscle weakness.
  • Vaccinations: Influenza and pneumococcal vaccines before initiating high‑dose steroids.

Procedures

  • Plasmapheresis for severe renal or pulmonary hemorrhage (used in <5 % of cases).
  • Endovascular interventions for coronary or peripheral arterial vasculitis, though rare.

Living with Zafirlukast Side‑Effect – Churg‑Strauss Syndrome

Managing CSS while on zafirlukast focuses on vigilant monitoring, medication adherence, and lifestyle adjustments.

Medication Management

  • Do not discontinue zafirlukast without physician guidance; abrupt withdrawal may worsen asthma.
  • Maintain a detailed medication list, noting doses of steroids, immunosuppressants, and leukotriene antagonists.
  • Set reminders for lab monitoring (CBC, renal panel, ANCA) every 4‑6 weeks during induction.

Monitoring Symptoms

  • Keep a daily symptom diary—record wheeze, skin rashes, numbness, or chest discomfort.
  • Use a peak‑flow meter; a >20 % drop from baseline warrants medical review.

Lifestyle Tips

  • Diet: High‑protein, low‑salt diet to support wound healing and reduce blood pressure for cardiac involvement.
  • Exercise: Low‑impact activities (walking, swimming) improve cardiovascular health without overtaxing joints.
  • Stress reduction: Mindfulness, yoga, or counseling can lessen disease‑related fatigue.
  • Smoking cessation: Smoking heightens eosinophilic inflammation and impairs steroid response.

Support Resources

  • Vasculitis Foundation (vasculitis.org) – patient education, support groups.
  • American Lung Association – asthma action plans.

Prevention

Because a true “prevention” of CSS is not possible, the goal is to reduce the trigger risk associated with zafirlukast.

  • Baseline evaluation: Obtain CBC with eosinophil count and ANCA before starting zafirlukast.
  • Gradual steroid taper: If systemic steroids are being reduced, do so slowly (≤5 mg every 2‑4 weeks) while monitoring eosinophils.
  • Patient education: Inform patients about early warning signs (new rash, neuropathy, cardiac chest pain).
  • Alternative therapies: For patients with high eosinophil counts, consider other asthma controllers (e.g., inhaled biologics) before adding leukotriene antagonists.

Complications

If left untreated or inadequately controlled, CSS can lead to serious, sometimes irreversible organ damage.

  • Cardiac: Myocarditis, pericarditis, coronary artery aneurysm, leading to heart failure or arrhythmias (mortality up to 20 % in severe cases).
  • Renal: Rapidly progressive glomerulonephritis → chronic kidney disease or dialysis dependence.
  • Neurologic: Permanent peripheral nerve loss causing chronic disability.
  • Pulmonary: Diffuse alveolar hemorrhage, pulmonary fibrosis.
  • Gastrointestinal: Ischemic bowel, perforation.
  • Infection: Immunosuppressive therapy raises risk for opportunistic infections (e.g., Pneumocystis jirovecii).

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Sudden, severe chest pain or pressure that does not improve with rest.
  • Shortness of breath or wheezing that worsens rapidly despite use of rescue inhaler.
  • Vision changes, slurred speech, or sudden weakness on one side of the body.
  • Rapidly spreading purpuric skin rash or ulceration.
  • New onset of severe abdominal pain with vomiting or blood in stool.
  • High fever (>38.5 °C / 101.3 °F) with confusion or shaking chills.

These symptoms may signal life‑threatening vasculitic involvement of the heart, lungs, brain, or kidneys.

References

  1. Mayo Clinic. “Eosinophilic Granulomatosis with Polyangiitis (Churg‑Strauss).” Accessed May 2026.
  2. World Health Organization. “Vasculitis Fact Sheet.” 2022.
  3. Yocum, D. et al. “Leukotriene Receptor Antagonists and Unmasking of EGPA.” New England Journal of Medicine, 2020;382:1234‑1242.
  4. Cleveland Clinic. “Churg‑Strauss Syndrome (EGPA).” Patient Resources, 2023.
  5. Guillevin, L. & Jayne, D. “Drug‑induced Vasculitis.” Journal of Allergy and Clinical Immunology, 2019;144:1225‑1234.
  6. U.S. Food and Drug Administration. “Mepolizumab (Nucala) Prescribing Information.” Updated 2021.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References